Choose your preferred way to stay informed of new case launches and settlement deadlines
Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning “the Company’s disclosures regarding meetings with the United States Food and Drug Administration (the “FDA”) regarding the Company’s NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.” On this news, the price of the Company’s stock dropped.
In order to be eligible to join the ALLR class action lawsuit, you must have incurred a loss on shares of Allarity purchased during the class period listed above.
TOP
